Sign In
Buy CRMD
$8.23
+0.0600 (+0.734%)
At Close: Jun 03, 2026
CorMedix Rallies 60% YTD: Is This an Indication to Buy the Stock?
11:31am, Monday, 15'th Sep 2025
CRMD stock surges nearly 60% YTD as DefenCath drives strong sales, boosted by a $300M Melinta acquisition deal and raised revenue outlook.
CorMedix Inc. (CRMD) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript
01:18pm, Wednesday, 10'th Sep 2025
CorMedix Inc. (NASDAQ:CRMD ) Morgan Stanley 23rd Annual Global Healthcare Conference September 10, 2025 10:45 AM EDT Company Participants Joseph Todisco - CEO & Director Conference Call Participants R
CorMedix (CRMD) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
10:55am, Tuesday, 09'th Sep 2025
After losing some value lately, a hammer chart pattern has been formed for CorMedix (CRMD), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisi
Talphera Announces Private Placement Financing of up to $29 Million Priced At-the Market
08:30am, Monday, 08'th Sep 2025
CorMedix is making a strategic investment in Talphera as the lead investor, supported by existing stockholders Nantahala, Rosalind and Rock Springs with several new institutional investors $17 million
CorMedix Announces Strategic Minority Investment in Talphera
08:30am, Monday, 08'th Sep 2025
BERKELEY HEIGHTS, N.J., Sept. 08, 2025 (GLOBE NEWSWIRE) -- CorMedix Inc. (“CorMedix”) (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for
Wall Street Analysts Think CorMedix (CRMD) Could Surge 32.04%: Read This Before Placing a Bet
10:56am, Wednesday, 03'rd Sep 2025
The mean of analysts' price targets for CorMedix (CRMD) points to a 32% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts
Is DefenCath Sufficient to Support CorMedix's Long-Term Growth Path?
11:21am, Tuesday, 02'nd Sep 2025
CRMD's DefenCath, its only revenue source, posts $78.8M in sales in H1 2025, with exclusivity through 2033 fueling growth potential.
CorMedix Completes Acquisition of Melinta Therapeutics, Raises Financial Guidance and Announces New Leadership Team
07:30am, Tuesday, 02'nd Sep 2025
- Transformational deal for CorMedix that expands and diversifies company's commercial product portfolio, with seven innovative drug products and a pipeline expansion indication with near-term revenue
CorMedix to Participate in Upcoming Investor Conferences
08:30am, Thursday, 28'th Aug 2025
BERKELEY HEIGHTS, N.J., Aug. 28, 2025 (GLOBE NEWSWIRE) -- CorMedix Inc. (“CorMedix”) (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for
CorMedix: The Undervalued Breakthrough
02:41am, Tuesday, 26'th Aug 2025
CorMedix has achieved GAAP profitability after years of losses, with the market yet to fully price in this turnaround. Shares trade at a moderate 17x forward P/E, but with a projected 8x forward P/E,
Wall Street Analysts Believe CorMedix (CRMD) Could Rally 45.63%: Here's is How to Trade
10:56am, Monday, 18'th Aug 2025
The average of price targets set by Wall Street analysts indicates a potential upside of 45.6% in CorMedix (CRMD). While the effectiveness of this highly sought-after metric is questionable, the posit
Why CorMedix (CRMD) Might be Well Poised for a Surge
01:21pm, Thursday, 14'th Aug 2025
CorMedix (CRMD) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
CorMedix, Inc. (CRMD) Q2 2025 Earnings Call Transcript
03:16pm, Friday, 08'th Aug 2025
CorMedix, Inc. (NASDAQ:CRMD ) Q2 2025 Earnings Conference Call August 7, 2025 8:30 AM ET Company Participants Joseph Todisco - CEO & Director Matthew T. David - Executive VP & CFO Conference Call Part
CorMedix to Buy Melinta Therapeutics for $300 Million
10:49am, Thursday, 07'th Aug 2025
The buyer said the deal adds six marketed infectious-disease products to its offerings.
CorMedix (CRMD) Surpasses Q2 Earnings and Revenue Estimates
09:26am, Thursday, 07'th Aug 2025
CorMedix (CRMD) came out with quarterly earnings of $0.28 per share, beating the Zacks Consensus Estimate of $0.2 per share. This compares to a loss of $0.25 per share a year ago.
